Spanish blood products firm Grifols (GRLS.MC) expects to close its planned $4 billion takeover of peer Talecris (TLCR.O) at the beginning of June, following U.S. regulatory approval. "Once approval is received we expect to close the deal during the first days of June, thus starting the integration process," Grifols said in a statement after a shareholders' meeting in Barcelona on Tuesday. The statement from Grifols -- which makes medicines such as intravenous immune globulin (IVIG), albumin and other products from blood plasma -- indicated that the U.S. Federal Trade Commission's rubber stamp is near. Grifols' tie-up with Talecris will create the world's third-largest maker of blood plasma products, competing with Baxter International Inc (BAX.N) and Australia's CSL (CSL.AX).
Talecris Biotherapeutics Holdings Corp. (Talecris) is a biopharmaceutical company that produces and markets plasma-derived protein therapies. Shares of TLCR remained unchanged at $28.11. In the past year, the shares have traded as low as $15.70 and as high as $28.97. On average, 1120430 shares of TLCR exchange hands on a given day and today's volume is recorded at 12618.
Baxter International Inc. (Baxter) is a global, diversified healthcare company. Shares of BAX traded higher by 0.3% or $0.18/share to $59.23. In the past year, the shares have traded as low as $40.25 and as high as $60.50. On average, 3524100 shares of BAX exchange hands on a given day and today's volume is recorded at 237109.
Source
